What is the level of liabilities of GenKyoTex this year?
GenKyoTex has a debt balance of 0 this year.
GenKyoTex Liabilities 2024
GenKyoTex Liabilities
0
Ticker
GKTX.PA
ISIN
FR0013399474
WKN
A2PE0M
In 2024, GenKyoTex's total liabilities amounted to 0 , a 0% difference from the 0 total liabilities in the previous year.
GenKyoTex Aktienanalyse
What does GenKyoTex do?
GenKyoTex SA is a Swiss biotechnology company specializing in the development of innovative therapies for the treatment of inflammatory diseases. The company was founded in 2006 by Dr. Elias Papatheodorou and Dr. Takashi Mizuno and is headquartered near Lausanne. The history of GenKyoTex SA began with the discovery of a new enzyme called NOX (NADPH oxidase) 1/4, which plays a crucial role in the onset of inflammation. This was the starting point for the development of inhibitors that reduce NOX activity and thus halt the progression of inflammatory diseases such as fibrosis, arthritis, or kidney failure. GenKyoTex SA's business model is based on the development and marketing of therapeutics based on NOX inhibitor technology. The company works closely with leading experts and research institutions to develop innovative drugs and conduct clinical trials. The different divisions of GenKyoTex SA include expertise in formulation, manufacturing, and stabilization of active ingredients and drugs, as well as the development of clinical trials and optimization of production processes. The company has its own research and development department, allowing it to oversee the entire value chain associated with its products. The company has developed a range of products based on NOX inhibitor technology. One of these is GKT831, a drug used to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive condition in which lung tissue becomes inflamed and scarred, impairing oxygen uptake. GKT831 has shown promising results in a clinical program. Another product from GenKyoTex SA is GKT771, a drug used to treat patients with diabetic nephropathy. Diabetic nephropathy is a complication of diabetes in which kidney function deteriorates. GKT771 has shown positive results in a phase 2 study and is now in phase 3 development. Overall, GenKyoTex SA is an innovative company focused on the development of drugs for the treatment of inflammation. The company has expertise in NOX inhibitor technology and has already brought several promising products to market or in development. Thanks to collaboration with leading experts and research institutions, GenKyoTex SA can accelerate the development of new drugs and improve patients' quality of life. GenKyoTex ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing GenKyoTex's Liabilities
GenKyoTex's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GenKyoTex's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing GenKyoTex's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
GenKyoTex's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in GenKyoTex’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about GenKyoTex stock
What were the liabilities of GenKyoTex compared to the previous year?
The liabilities of GenKyoTex have increased by 0% dropped compared to the previous year.
What are the consequences of high debt for investors of GenKyoTex?
High liabilities can pose a risk for investors of GenKyoTex, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in GenKyoTex?
Low liabilities mean that GenKyoTex has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of GenKyoTex affect the company?
An increase in liabilities of GenKyoTex can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of GenKyoTex affect the company?
A decrease in the liabilities of GenKyoTex can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of GenKyoTex?
Some factors that can influence the liabilities of GenKyoTex include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of GenKyoTex so important for investors?
The liabilities of GenKyoTex are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can GenKyoTex take to modify the liabilities?
To change its liabilities, GenKyoTex can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does GenKyoTex pay?
Over the past 12 months, GenKyoTex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GenKyoTex is expected to pay a dividend of 0 .
What is the dividend yield of GenKyoTex?
The current dividend yield of GenKyoTex is .
When does GenKyoTex pay dividends?
GenKyoTex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of GenKyoTex?
GenKyoTex paid dividends every year for the past 0 years.
What is the dividend of GenKyoTex?
For the upcoming 12 months, dividends amounting to 0 are expected. This corresponds to a dividend yield of 0 %.
In which sector is GenKyoTex located?
GenKyoTex is assigned to the 'Health' sector.
Wann musste ich die Aktien von GenKyoTex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of GenKyoTex from 10/1/2024 amounting to 0 , you needed to have the stock in your portfolio before the ex-date on 10/1/2024.
When did GenKyoTex pay the last dividend?
The last dividend was paid out on 10/1/2024.
What was the dividend of GenKyoTex in the year 2023?
In the year 2023, GenKyoTex distributed 0 as dividends.
In which currency does GenKyoTex pay out the dividend?
The dividends of GenKyoTex are distributed in .
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von GenKyoTex
Our stock analysis for GenKyoTex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GenKyoTex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
